Similarly, theabrownin, derived from Pu-erh tea, acts as an intestinal farnesoid X receptor (FXR) antagonist to mitigate NAFLD by inhibiting the intestinal FXR-ceramide axis. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.